A nutritional composition capable of promoting brain development and its use

Abstract

The present invention relates to a nutritional composition for promoting brain development, which is composed of DHA, tocotrienols, vitamin B, lysine, lecithin and a pharmaceutical carrier. The rat dark avoidance test and the Morris water maze test have fully proved that the drug components of DHA, tocotrienols, vitamin B, lysine and lecithin have an obvious synergistic effect on promoting brain development. 50 , CI 75 and CI 90 The values ​​are all less than 1.0, and the synergistic effect between them is very significant.

Description

[Technical field]

[0001] The present invention belongs to the technical field of food production. More specifically, the present invention relates to a nutritional composition capable of promoting brain development, and also relates to the use of the nutritional composition capable of promoting brain development. [Background technology]

[0002] Docosahexaenoic acid (DHA) is a very important n-3 series polyunsaturated fatty acid for the human body. It mainly exists in the human brain, nerve cells and retinal tissue in the form of phospholipids, and plays an important role in the growth and development of the human brain and nervous system. The brain is the higher center of the nervous system, which controls and regulates the functional activities of various systems in the body. The development of the infant brain plays an important role in the future intellectual development. The material basis of brain development is various nutrients. Nutritional deficiencies will have a profound impact on the normal brain development process, especially the critical period of brain cell proliferation, differentiation and functional network formation.

[0003] Currently, products that promote brain development on the market use DHA, protein, taurine, phosphatidylserine, vitamins, zinc, etc. as main raw materials. Their main mechanism for promoting brain development is to promote the growth and development of brain cells and promote brain cell proliferation. Although these products can provide the nutritional basis for brain growth and development, the brain development of infants and young children is affected by various aspects, such as the synthesis of neurotransmitters, information transmission between neurons, oxidative stress damage to brain cells, and brain energy metabolism. Therefore, research on new products that can promote the brain development of infants and young children in many aspects has become a new trend. For example, CN 116098199A discloses a formula milk powder and a preparation method for promoting children's memory in the field of milk powder processing technology, comprising the following components in parts by weight: 350-450 parts of skimmed milk powder, 300-400 parts of whole milk powder, 350-450 parts of desalted whey powder, 2-8 parts of lecithin, 1-5 parts of docosahexaenoic acid, 3-7 parts of ARA, 4-8 parts of walnut peptides, 3-9 parts of phosphatidylserine, 1-6 parts of tryptophan, 2-7 parts of lysine, 0.3-0.8 parts of composite Chinese medicine extract, 0.5-1.4 parts of composite prebiotics, 0.2-1.2 parts of composite vitamins and 0.6-1.8 parts of composite minerals. The formula milk powder can provide sufficient nutrition for children's growth, improve children's immunity, promote bone growth, enhance gastrointestinal digestion ability and improve children's sleep quality, so that children can develop synchronously in physical and intellectual development, thereby promoting children's memory. However, this technology has the technical defects of complex formula ingredients, single function of each ingredient and inability to work synergistically.

[0004] In view of the technical defects of the prior art, the inventors have completed the present invention through a large number of experimental studies and analytical summaries based on the summary of the prior art. [Summary of the invention]

[0005] [Technical issues to be solved]

[0006] The object of the present invention is to provide a nutritional composition capable of promoting brain development.

[0007] Another object of the present invention is to provide use of the nutritional composition capable of promoting brain development.

[0008] [Technical solution]

[0009] The present invention is achieved through the following technical solutions.

[0010] The invention relates to a nutritional composition capable of promoting brain development.

[0011] The nutritional composition comprises the following components: by weight:

[0012]

[0013] According to a preferred embodiment of the present invention, the nutritional composition comprises the following: in parts by weight:

[0014]

[0015] According to another preferred embodiment of the present invention, the nutritional composition comprises the following: in parts by weight:

[0016]

[0017] According to another preferred embodiment of the present invention, the pharmaceutical carrier is one or more pharmaceutical carriers selected from maltodextrin, resistant dextrin, D-mannitol, maltitol, erythritol, xylitol, sorbitol, microcrystalline cellulose, starch, sucrose, glucose, lactose, pectin, citric acid, phospholipids, mono- and di-stearin, steviol glycosides, vegetable oils, purified water or magnesium stearate.

[0018] According to another preferred embodiment of the present invention, the pharmaceutical carrier is one or more pharmaceutical carriers selected from maltodextrin, D-mannitol, maltitol, erythritol, xylitol, sorbitol, microcrystalline cellulose, glucose, lactose, pectin, citric acid, phospholipids, vegetable oil or magnesium stearate.

[0019] According to another preferred embodiment of the present invention, the docosahexaenoic acid is a docosahexaenoic acid algae oil solution with a concentration of 45-55% by weight.

[0020] According to another preferred embodiment of the present invention, the tocotrienol is a tocotrienol powder with a content of 55-65% by weight.

[0021] According to another preferred embodiment of the present invention, the dosage form of the nutritional composition is tablets, powders, granules, capsules or beverages.

[0022] The present invention also relates to the use of the nutritional composition in infant formula milk powder, infant complementary food or nutritional supplement.

[0023] According to another preferred embodiment of the present invention, the content of the nutritional composition in the infant formula milk powder, infant complementary food or nutritional supplement is 5-20%, 5-10% or 20-50% by weight respectively.

[0024] The present invention will be described in more detail below.

[0025] The present invention relates to a nutritional composition capable of promoting brain development. The inventor prepares a nutritional composition from active substances such as docosahexaenoic acid (DHA) and tocotrienol, which can promote the growth and development of brain cells, enhance the information transmission between brain neurons, and reduce the damage of oxidative stress to brain cells, so as to achieve the effect of promoting brain development.

[0026] The nutritional composition comprises the following components: by weight:

[0027] 100-300 parts of docosahexaenoic acid; 100-400 parts of tocotrienol;

[0028] Vitamin B 1-5 parts; Lysine 1000-3000 parts;

[0029] 500-2000 parts of lecithin; 0-1000 parts of pharmaceutical carrier.

[0030] Docosahexaenoic acid (DHA) is the main component of the human brain and is very important for brain development.

[0031] According to the present invention, the main function of DHA in the nutritional composition of the present invention is that it can penetrate the brain barrier directly to the important position of the brain, increase the synapses of brain nerve cells, activate the brain nerve function, and enhance the nerve conduction signals of brain cells, thereby promoting brain development and enhancing the intelligence of infants and young children. The docosahexaenoic acid used in the present invention is a docosahexaenoic acid algae oil solution with a concentration of 45-55% by weight, which is a product currently sold on the market, such as a product sold by Haisifu Bioengineering Co., Ltd. under the trade name DHA oil.

[0032] Tocotrienol is a natural vitamin E, which can be divided into α, β, γ, and δ types according to the number and position of methyl groups on its aromatic ring. Tocotrienol has strong antioxidant properties, which helps to protect the normal structure of the brain and maintain its normal function.

[0033] According to the present invention, the main function of tocotrienol in the nutritional composition of the present invention is that it can neutralize free radicals, reduce the damage of oxidative stress to brain cells, thereby protecting the brain from damage and maintaining healthy brain development. The tocotrienol used in the present invention is a tocotrienol powder with a content of 55-65% by weight, which is a product currently sold on the market, such as a product sold by Xi'an Tongze Biotechnology Co., Ltd. under the trade name tocotrienol.

[0034] Vitamin B is a water-soluble vitamin that promotes metabolism in the body and is an indispensable substance that can convert sugar, fat, protein, etc. into energy required by the human body. Among them, vitamin B12 is an important auxiliary factor in the synthesis of neurotransmitters and is essential for maintaining normal brain function.

[0035] According to the present invention, the main function of vitamin B in the nutritional composition of the present invention is to promote the growth and division of brain cells, contribute to the normal development of neurons, and promote the connection and information transmission of brain neurons. The vitamin B used in the present invention is a product currently sold on the market, such as a product sold by Jiangsu Yuanzhiyuan Biotechnology Co., Ltd. under the trade name vitamin B12.

[0036] Lysine is an essential nutrient for neuron growth and synapse formation. It plays a vital role in neuron growth and synapse formation.

[0037] According to the present invention, the main role of lysine in the nutritional composition of the present invention is to participate in the synthesis of neurotransmitters, contribute to the information transmission between neurons, maintain the energy metabolism of the brain, and improve cognitive functions, including attention, memory, thinking ability and learning ability. The lysine used in the present invention is a product currently sold on the market, such as a product sold by Hebei Hongzhitao Biotechnology Co., Ltd. under the trade name L-lysine.

[0038] Lecithin is a mixture of substances such as phosphoric acid, choline, fatty acids, glycerol, glycolipids, triglycerides and phospholipids. It is the raw material for the synthesis of the neurotransmitter acetylcholine, which can promote the growth and connection of brain neurons and improve brain function.

[0039] According to the present invention, the main function of lecithin in the nutritional composition of the present invention is to synthesize acetylcholine, improve the learning and memory ability of the brain; promote the growth and differentiation of brain neurons, establish complex neural networks and connections; improve brain blood circulation, provide sufficient nutrients and oxygen to the brain, maintain the normal function of the brain, and improve attention and reaction ability. The lecithin used in the present invention is a product currently sold on the market, such as a product sold by Guangzhou Jingfu Bioengineering Co., Ltd. under the trade name soybean lecithin.

[0040] Pharmaceutical carriers are pharmaceutically acceptable carriers commonly used in the existing pharmaceutical industry. They can change the way drugs enter the human body and their distribution in the body, control the rate of drug release, improve the utilization, safety and effectiveness of drugs, and deliver drugs to targeted organs.

[0041] According to the present invention, the main function of the pharmaceutical carrier in the nutritional composition of the present invention is to promote the compatibility of the components, protect the components to play a better role, and improve the utilization rate and effectiveness of the composition. The pharmaceutical carrier used in the present invention is one or more pharmaceutical carriers selected from maltodextrin, resistant dextrin, D-mannitol, maltitol, erythritol, xylitol, sorbitol, microcrystalline cellulose, starch, sucrose, glucose, lactose, pectin, citric acid, phospholipids, mono- and di-stearate glycerides, steviol glycosides, vegetable oils, purified water or magnesium stearate, which are all products currently sold on the market, such as maltodextrin sold by Xi'an Tianzheng Pharmaceutical Excipients Co., Ltd. under the trade name maltodextrin, sold by Henan Letai Food Co., Ltd. under the trade name maltodextrin, and sold by Henan Letai Food Co., Ltd. under the trade name maltodextrin. D-mannitol sold under the trade name D-mannitol, erythritol sold under the trade name erythritol by Shaanxi Chenming Biotechnology Co., Ltd., microcrystalline cellulose sold under the trade name microcrystalline cellulose by Shandong Xinda Biotechnology Co., Ltd., phospholipids sold under the trade name soy lecithin by Guangzhou Jingfu Bioengineering Co., Ltd., mono- and distearic acid glyceryl sold under the trade name distearic acid glyceryl by Xi'an Tianzheng Pharmaceutical Excipients Co., Ltd., and steviol glycosides sold under the trade name steviol glycosides by Xi'an Tianzheng Pharmaceutical Excipients Co., Ltd.

[0042] Preferably, the pharmaceutical carrier is one or more pharmaceutical carriers selected from maltodextrin, D-mannitol, maltitol, erythritol, xylitol, sorbitol, microcrystalline cellulose, glucose, lactose, pectin, citric acid, phospholipids, vegetable oil or magnesium stearate.

[0043] According to the present invention, when the contents of tocotrienol, vitamin B, lysine, lecithin and pharmaceutical carrier are within the range, if the content of DHA is less than 100 parts, the brain nerve function cannot be well activated and the brain cell nerve conduction signal cannot be effectively enhanced; if the content of DHA is higher than 300 parts, the brain nerve function cannot be effectively activated and the brain cell nerve conduction signal cannot be effectively enhanced due to the increase in the absorption and digestion burden caused by the excessive content; therefore, it is reasonable for the content of DHA to be 100 to 300 parts, preferably 140 to 260 parts; more preferably 160 to 240 parts;

[0044] When the contents of DHA, vitamin B, lysine, lecithin and pharmaceutical carrier are within the above ranges, if the content of tocotrienol is less than 100 parts, it cannot well reduce the damage of oxidative stress to brain cells, and thus cannot play a role in maintaining the healthy development of the brain; if the content of tocotrienol is higher than 400 parts, it cannot effectively reduce the damage of oxidative stress to brain cells due to the side effects of excessive intake, and cannot play a role in maintaining the healthy development of the brain; therefore, the content of tocotrienol is suitably 100 to 400 parts, preferably 160 to 350 parts; more preferably 180 to 320 parts;

[0045] When the contents of DHA, tocotrienols, lysine, lecithin and pharmaceutical carriers are within the above ranges, if the content of vitamin B is less than 1 part, it cannot effectively promote the growth and division of brain cells and the normal development of neurons, and thus cannot effectively promote the connection and information transmission of brain neurons; if the content of vitamin B is higher than 5 parts, it cannot effectively promote the growth and division of brain cells and the normal development of neurons due to excessive nerve excitability or allergic reactions caused by excessive intake, and cannot effectively promote the connection and information transmission of brain neurons; therefore, a content of vitamin B of 1 to 5 parts is appropriate, preferably 2 to 4 parts;

[0046] When the contents of DHA, tocotrienols, vitamin B, lecithin and pharmaceutical carrier are within the range, if the content of lysine is less than 1000 parts, it cannot promote the growth and connection of brain neurons well, and thus cannot improve brain function; if the content of lysine is higher than 3000 parts, it cannot effectively promote the growth and connection of brain neurons due to the developmental effects or digestive stimulation caused by excessive intake, and cannot improve brain function; therefore, it is reasonable that the content of lysine is 1000 to 3000 parts, preferably 1400 to 2600 parts; more preferably 1600 to 2400 parts;

[0047] When the contents of DHA, tocotrienols, vitamin B, lysine and pharmaceutical carriers are within the above ranges, if the content of lecithin is less than 500 parts, it cannot improve the blood circulation of the brain, cannot provide sufficient nutrients and oxygen to the brain, and thus cannot play a role in maintaining the normal function of the brain; if the content of lecithin is higher than 2000 parts, it cannot provide sufficient nutrients and oxygen to the brain due to indigestion or allergic reactions caused by excessive intake, and effectively maintain the normal function of the brain; therefore, the content of lecithin is appropriately 500-2000 parts, preferably 600-1800 parts; more preferably 800-1600 parts;

[0048] When the contents of DHA, tocotrienols, vitamin B, lysine and lecithin are within the described ranges, the content of the pharmaceutical carrier can be zero when a fast and efficient composition is required; if the content of the pharmaceutical carrier is higher than 1000 parts, the effect is not good due to the high proportion of the pharmaceutical carrier, which reduces the content of each active ingredient; therefore, a content of the pharmaceutical carrier of 0 to 1000 parts is desirable, preferably 40 to 500 parts, and more preferably 100 to 300 parts.

[0049] Preferably, the nutritional composition is composed as follows: based on the weight of the following components,

[0050] 140-260 parts of docosahexaenoic acid; 160-350 parts of tocotrienol;

[0051] Vitamin B 2-4 parts; Lysine 1400-2600 parts;

[0052] 600-1800 parts of lecithin; 40-500 parts of pharmaceutical carrier.

[0053] More preferably, the nutritional composition is composed of the following components in parts by weight:

[0054] 160-240 parts of docosahexaenoic acid; 180-320 parts of tocotrienol;

[0055] Vitamin B 2-4 parts; Lysine 1600-2400 parts;

[0056] 800-1600 parts of lecithin; 100-300 parts of pharmaceutical carrier.

[0057] According to the present invention, the dosage form of the nutritional composition is tablets, powders, granules, capsules or beverages.

[0058] In the present invention, the tablet dosage form of the nutritional composition of the present invention is prepared according to the preparation method disclosed in CN118178430A.

[0059] The powder dosage form of the nutritional composition of the present invention is prepared according to the preparation method disclosed in CN114532519 A.

[0060] The granular dosage form of the nutritional composition of the present invention is prepared according to the preparation method disclosed in CN114532519 A.

[0061] The capsule dosage form of the nutritional composition of the present invention is prepared according to the preparation method disclosed in CN108210544A.

[0062] The nutritional composition beverage dosage form of the present invention is prepared according to the preparation method disclosed in CN107158025 A.

[0063] The present invention also relates to the use of the nutritional composition in infant formula milk powder, infant complementary food or nutritional supplement.

[0064] In the present invention, infant formula milk powder should be understood as a milk powder that is a comprehensive nutritional supplement with raw cow / goat milk or milk powder as the main raw material, and its nutritional composition content is 5-20% by weight. If its nutritional composition content is lower than 5% by weight, it cannot play its role due to too low content; if its nutritional composition content is higher than 20% by weight, the content of each component will be unbalanced due to excessive amount, and it cannot provide nutrients comprehensively; therefore, it is appropriate for its nutritional composition content to be 5-20% by weight;

[0065] Infant and young children's complementary food should be understood as a kind of food that supplements nutrition in addition to breast milk or milk powder, and its nutritional composition content is 5-10% by weight. If its nutritional composition content is lower than 5% by weight, it cannot play its role due to too low content; if its nutritional composition content is higher than 10% by weight, it will cause the content of other ingredients in the complementary food to be unbalanced due to excessive content, and it will not be able to provide nutrients comprehensively; therefore, its nutritional composition content of 5-10% by weight is appropriate;

[0066] Nutritional supplements should be understood as a kind of food that supplements nutrients in addition to diet, and its nutritional composition content is 20-50% by weight. If its nutritional composition content is lower than 20% by weight, it cannot achieve the purpose of nutritional supplementation due to too low content; if its nutritional composition content is higher than 50% by weight, it may cause some reactions such as inability to absorb or allergies due to excessive intake; therefore, it is appropriate for its nutritional composition content to be 20-50% by weight.

[0067] [Beneficial Effects]

[0068] The beneficial effects of the present invention are:

[0069] In the composition of the present invention, DHA, tocotrienols, vitamin B, lysine and lecithin can not only give full play to their respective effects, but also have a synergistic effect. Tocotrienols can reduce the damage of oxidative stress to brain cells while also having an antioxidant and anti-peroxidation effect on DHA, which enables the DHA in the composition to better activate brain nerves and enhance brain nerve conduction signals; the combination of appropriate doses of DHA and vitamin B can enable vitamin B to better promote the growth and development of brain cells; lecithin can activate cell functions in the body, thereby doubling the effects of DHA, tocotrienols, vitamin B and lysine. By optimizing the content of each component, the purpose of achieving a significant synergistic effect on the overall efficacy can be achieved. The rat dark avoidance experiment and Morris water maze experiment proved that the drug components of DHA, tocotrienols, vitamin B, lysine and lecithin have obvious synergistic effects on promoting brain development, and their CI50, CI75 and CI90 values ​​are all less than 1.0. Moreover, the synergistic effect between the drug components of the combination is most significant when the mass ratio of the drug components is 300:350:2:3000:1100. [Specific implementation method]

[0070] The present invention will be better understood through the following examples.

[0071] Example 1: Nutritional composition tablets of the present invention

[0072] The implementation of this embodiment is as follows:

[0073] According to the preparation method disclosed in CN118178430 A, a GZP250 series intelligent rotary tablet press is used to mix 130 parts by weight of DHA algae oil solution, 100 parts by weight of tocotrienol powder, 1 part by weight of vitamin B, 2200 parts by weight of lysine, 500 parts by weight of lecithin and 100 parts by weight of D-mannitol pharmaceutical carrier to prepare the nutritional composition tablets of the present invention.

[0074] Example 2: Nutritional composition powder of the present invention

[0075] The implementation of this embodiment is as follows:

[0076] According to the preparation method disclosed in CN114532519 A, a plowshare mixer is used to mix 160 parts by weight of DHA algae oil solution, 140 parts by weight of tocotrienol powder, 5 parts by weight of vitamin B, 1000 parts by weight of lysine, 700 parts by weight of lecithin and 200 parts by weight of maltitol pharmaceutical carrier to prepare the nutritional composition powder of the present invention.

[0077] Example 3: Nutrient composition granules of the present invention

[0078] The implementation of this embodiment is as follows:

[0079] According to the preparation method disclosed in CN114532519 A, a wet granulator GLH-1 is used to mix 100 parts by weight of DHA algae oil solution, 400 parts by weight of tocotrienol powder, 3 parts by weight of vitamin B, 2800 parts by weight of lysine, 1500 parts by weight of lecithin and 100 parts by weight of microcrystalline cellulose pharmaceutical carrier to prepare a nutritional composition granule.

[0080] Example 4: Nutritional composition capsules of the present invention

[0081] The implementation of this embodiment is as follows:

[0082] According to the preparation method disclosed in CN108210544 A, 300 parts by weight of DHA algae oil solution, 350 parts by weight of tocotrienol powder, 2 parts by weight of vitamin B, 3000 parts by weight of lysine, 1100 parts by weight of lecithin and 100 parts by weight of glucose pharmaceutical carrier are mixed using a plowshare mixer to prepare the nutritional composition capsules of the present invention.

[0083] Example 5: Nutritional composition beverage of the present invention

[0084] The implementation of this embodiment is as follows:

[0085] According to the preparation method disclosed in CN107158025 A, 270 parts by weight of DHA algae oil solution, 300 parts by weight of tocotrienol powder, 4 parts by weight of vitamin B, 1300 parts by weight of lysine, 1700 parts by weight of lecithin and 100 parts by weight of citric acid medicinal carrier are mixed using a plowshare mixer to prepare the nutritional composition beverage of the present invention.

[0086] Example 6: Nutritional composition tablets of the present invention

[0087] The implementation of this embodiment is as follows:

[0088] According to the preparation method disclosed in CN118178430 A, a GZP250 series intelligent rotary tablet press is used to mix 240 parts by weight of DHA algae oil solution, 260 parts by weight of tocotrienol powder, 2 parts by weight of vitamin B, 1600 parts by weight of lysine, 1300 parts by weight of lecithin and 100 parts by weight of mono- and distearic acid glyceryl pharmaceutical carrier to prepare the nutritional composition tablets of the present invention.

[0089] Example 7: Nutrient composition granules of the present invention

[0090] The implementation of this embodiment is as follows:

[0091] According to the preparation method disclosed in CN114532519 A, a wet granulator GLH-1 is used to mix 190 parts by weight of DHA algae oil solution, 180 parts by weight of tocotrienol powder, 3 parts by weight of vitamin B, 2500 parts by weight of lysine, 2000 parts by weight of lecithin and 100 parts by weight of erythritol pharmaceutical carrier to prepare the granules of the nutritional composition of the present invention.

[0092] Example 8: Nutritional composition powder of the present invention

[0093] The implementation of this embodiment is as follows:

[0094] According to the preparation method disclosed in CN114532519 A, 100 parts by weight of DHA algae oil solution, 220 parts by weight of tocotrienol powder, 1 part by weight of vitamin B, 1900 parts by weight of lysine, 900 parts by weight of lecithin and 100 parts by weight of magnesium stearate pharmaceutical carrier are mixed using a plowshare mixer to prepare the nutritional composition powder of the present invention.

[0095] Test Example 1:

[0096] The implementation method of this test example is as follows:

[0097] I. Experimental Animals:

[0098] 10 SD male rats, 4 weeks old, weighing 100 ± 10 g;

[0099] II. Test samples:

[0100] (i) samples of the nutritional composition of the present invention prepared in Examples 1-8;

[0101] (ii) The comparative test samples are as follows:

[0102] Comparative sample 1 is DHA;

[0103] Comparative sample 2 is tocotrienol;

[0104] Comparative sample 3 is vitamin B;

[0105] Comparative sample 4 is lysine;

[0106] Comparative sample 5 is lecithin;

[0107] Comparative sample 6 is a mixture of DHA and tocotrienol (weight ratio 1.3:1.0);

[0108] Comparative sample 7 is a mixture of DHA and vitamin B (weight ratio 32:1);

[0109] Comparative sample 8 is a mixture of DHA and lysine (weight ratio 1:28);

[0110] Comparative sample 9 is a mixture of DHA and lecithin (weight ratio 3:11);

[0111] Comparative sample 10 is a mixture of DHA, tocotrienols and vitamin B (weight ratio 300:350:2);

[0112] Comparative sample 11 is a mixture of DHA, tocotrienols and lysine (weight ratio 27:30:13);

[0113] Comparative sample 12 is a mixture of DHA, tocotrienols and lecithin (weight ratio 24:26:13);

[0114] Comparative sample 13 is a mixture of DHA, tocotrienols, vitamin B and lysine (weight ratio 19:18:3:25);

[0115] Comparative sample 14 is a mixture of DHA, tocotrienol, vitamin B and lecithin (weight ratio 100:220:1:900).

[0116] Add pure water as a blank test.

[0117] Test sample dosage:

[0118] According to the method described by Wei Wei, "Pharmacological Experimental Methodology", People's Medical Publishing House (July 1, 2010), each SD male rat was intragastrically administered with 33 mg / kg (body weight) of the above test sample every day.

[0119] III. Test equipment:

[0120] A. Dark avoidance experiment instrument: The instrument is divided into two chambers, light and dark. The light chamber is 30cmx30cmx20cm, and a 30W tungsten filament is hung about 20cm above it. The dark chamber is 30cmx30cmx20cm, and a round hole with a diameter of about 3cm is set between the two chambers. The bottom of both chambers is paved with copper grids. The middle copper grid at the bottom of the dark chamber can pass 40V voltage, and the electric shock intensity is selected by the knob. The dark avoidance experiment instrument is a product sold by Tianjin Norexinda Technology Co., Ltd. under the trade name Tianjin Norexinda YLS-17B Dark Avoidance Shuttle Tester Pharmacological Experiment Instrument.

[0121] B. Morris water maze experimental apparatus: The Morris water maze experimental system consists of a circular water pool and an automatic image acquisition and processing system. The automatic image acquisition and processing system mainly consists of a camera, a computer and an image monitor. The circular water pool is a cylindrical water bucket with a diameter of 160 cm, a height of 50 cm, a depth of 30 to 40 cm, and a circular platform with a diameter of 12 cm set 1 cm below the water surface. There must be no marks in the water pool. Four marking points A, B, C and D are set at equal distances on the upper edge of the barrel as the entry points for animals to enter the water pool. The projection points of these four entry points on the water surface and the bottom of the bucket are used as reference points. The water surface and the bucket part are divided into four quadrants. According to the experimental requirements, the platform can be arbitrarily set in the middle of a quadrant. The Morris water maze experimental apparatus is a product sold by Shanghai Xinruan Information Technology Co., Ltd. under the trade name Morris Water Maze Experiment Analysis System for Rats and Mice.

[0122] C. Instrument for determination of acetylcholine content: acetylcholine (ACh) ELISA test kit (Shanghai Xiangsheng Biotechnology Co., Ltd.), microplate reader (450 nm).

[0123] IV. Test methods

[0124] A. Dark avoidance test method:

[0125] Place SD male rats in the light chamber of the above-mentioned dark avoidance experimental apparatus and adapt for 2 minutes (the dark chamber is not powered on, and the rats can move freely between the light and dark chambers), then power on the dark chamber and train for 5 minutes (the rats can move freely between the light and dark chambers). The test begins 24 hours later, the dark chamber is powered on, and the rats are placed in the light chamber with their faces facing away from the hole. At the same time, the timer is started. After the rats pass through the round hole and enter the dark chamber, the middle shuttle hole is closed and the test continues for 5 minutes. The time required for each rat from being placed in the light chamber to entering the hint and receiving an electric shock is the latency period. Record the percentage of rats entering the dark chamber (wrong response), the latency period of each rat entering the dark chamber, and the number of electric shocks each rat receives within 5 minutes after entering the dark chamber.

[0126] B. Morris water maze test method:

[0127] The test method includes positioning navigation test and space exploration test.

[0128] The positioning navigation experiment was carried out for 4 days. SD male rats were trained 4 times a day and were put into the water from fixed positions in 4 quadrants respectively. The time required for the rats to find the underwater platform was recorded for each training session (if the rats did not find the platform within 120 s, they were led to the platform and placed there for 10 s, and the time was recorded as 120 s at this time). The average value of the 4 training times per day was the escape latency. On the first day after the positioning navigation experiment, a space exploration experiment was carried out. The underwater platform was removed and the first quadrant was used as the entry point. The number of times the rats crossed the platform within 2 min and the activity time in the quadrant where the platform was located were recorded.

[0129] C. Acetylcholine content determination method:

[0130] The SD male rats that had been gavage-fed for 60 days were killed, and the brain tissue was removed and mashed with physiological saline. The brain tissue was centrifuged at 3000 rpm for 10 minutes using a centrifuge sold by Shenzhen Ruiwode Life Science Co., Ltd. under the trade name of high-speed refrigerated centrifuge, and the supernatant was removed and the acetylcholine content of the supernatant was detected according to the method described in the operating instructions of the above instrument kit.

[0131] V. Test Results

[0132] A. Dark avoidance test results

[0133] The dark avoidance test results of the nutritional composition samples prepared in Examples 1-8 and the comparative test samples are listed in Table 1.

[0134] Table 1: Dark avoidance test results

[0135]

[0136]

[0137] It can be seen from the test results listed in Table 1 that, compared with DHA, tocotrienols, vitamin B, lysine, lecithin and other comparative test samples, the results of the dark avoidance test of rats prepared by the nutritional composition of the embodiment of the present invention show that the percentage of rats entering the dark room is lower, the latency period is longer, and the number of electric shocks is less, indicating that there is an obvious synergistic effect between DHA, tocotrienols, vitamin B, lysine and lecithin in the nutritional composition of the present invention, and there is a significant improvement in cognitive ability and memory improvement, and the effect of promoting brain development is obvious.

[0138] B. Morris water maze test results

[0139] The results of the positioning navigation test of the nutrient composition samples prepared in Examples 1-8 and the comparative test samples are listed in Table 2 below, and the results of the space exploration test are listed in Table 3 below.

[0140] Table 2: Results of positioning navigation test

[0141]

[0142]

[0143] Table 3: Space exploration test results

[0144]

[0145]

[0146] It can be seen from the test results listed in Tables 2 and 3 that the nutritional composition of the embodiment of the present invention is applied to the Morris water maze test of rats. Compared with DHA, tocotrienols, vitamin B, lysine, lecithin and their combination, the escape latency is significantly shortened, the number of times the platform is crossed and the activity time in the quadrant where the platform is located are increased, indicating that there is a significant synergistic effect between DHA, tocotrienols, vitamin B, lysine and lecithin in the nutritional composition of the present invention, and there is a significant improvement in cognitive ability and memory improvement, and the effect of promoting brain development is obvious.

[0147] C. Acetylcholine content determination results

[0148] The results of the acetylcholine content determination of the nutritional composition samples prepared in Examples 1-8 and the comparative test samples are listed in Table 4 below.

[0149] Table 4: Acetylcholine content determination results

[0150]

[0151]

[0152] The acetylcholine content determination results listed in Table 4 show that compared with the blank test, the acetylcholine content of the rat brain tissue in each test group is significantly increased, wherein the acetylcholine content increase rates of Examples 1-8 are 220.7%, 259.7%, 240.9%, 284.6%, 203.5%, 182.2%, 193.7% and 172.8%, respectively; the increase rates of Comparative Tests 1-5 are 59.8%, 53.6%, 36.4%, 51.6% and 28.1%, respectively; compared with Comparative Tests 1-5, the acetylcholine content of Examples 1-8 is also significantly increased, wherein the increases in Examples 2 and 4 are extremely significant.

[0153] According to the software CompuSyn of ComboSyn, the Combination Index (CI) is calculated by analyzing the test results in the examples. The synergistic effect between drugs is evaluated based on the CI to show the strength of the synergistic effect of the drugs:

[0154] CI>1 indicates that there is a synergistic effect between drug components, and combined use can enhance the efficacy of each monomer drug. The smaller the CI value, the stronger the synergistic effect;

[0155] CI = 1 means that there is an additive effect between the drug components, and the combined drug results are just the linear superposition of the therapeutic effects of each drug component;

[0156] CI>1 means that there is antagonism between the drug components, and combined use will reduce the efficacy of each drug component.

[0157] Table 5 below lists the combined drug index CI values ​​of each composition of Examples 1-8.

[0158] Table 5: Combination Drug Index (CI) of Examples 1-8

[0159]

[0160]

[0161] From the results in Table 5, it can be seen that the combination coefficients CI of the compositions of Examples 1-8 are all less than 1, indicating that the components of these compositions exhibit synergistic effects. The combination coefficients of the compositions of Examples 1, 2, 3 and 4 are all less than 0.60, showing strong synergistic effects. The average combination index (CI) of the composition of Example 4 is avg ) was 0.48, which is the lowest mean value of the combined medication index, indicating that it has a more obvious effect in promoting brain development.

Claims

1. A nutritional composition capable of promoting brain development, characterized in that The nutritional composition comprises the following components: by weight: 100-300 parts of docosahexaenoic acid; 100-400 parts of tocotrienol; Vitamin B 1-5 parts; Lysine 1000-3000 parts; 500-2000 parts of lecithin; 0-1000 parts of pharmaceutical carrier; The docosahexaenoic acid is a docosahexaenoic acid algae oil solution with a concentration of 45-55% by weight, and the tocotrienol is a tocotrienol powder with a content of 55-65% by weight.

2. The nutritional composition according to claim 1, characterized in that The nutritional composition comprises the following components: by weight: 140-260 parts of docosahexaenoic acid; 160-350 parts of tocotrienol; Vitamin B 2-4 parts; Lysine 1400-2600 parts; 600-1800 parts of lecithin; 40-500 parts of pharmaceutical carrier.

3. The nutritional composition according to claim 1, characterized in that The nutritional composition comprises the following components: by weight: 160-240 parts of docosahexaenoic acid; 180-320 parts of tocotrienol; Vitamin B 2-4 parts; Lysine 1600-2400 parts; 800-1600 parts of lecithin; 100-300 parts of pharmaceutical carrier.

4. The nutritional composition according to claim 1, characterized in that The pharmaceutical carrier is one or more pharmaceutical carriers selected from maltodextrin, resistant dextrin, D-mannitol, maltitol, erythritol, xylitol, sorbitol, microcrystalline cellulose, starch, sucrose, glucose, lactose, pectin, citric acid, phospholipids, mono- and di-stearate glyceryl, steviol glycosides, vegetable oils, purified water or magnesium stearate.

5. The nutritional composition according to claim 1, characterized in that The pharmaceutical carrier is one or more pharmaceutical carriers selected from maltodextrin, D-mannitol, maltitol, erythritol, xylitol, sorbitol, microcrystalline cellulose, glucose, lactose, pectin, citric acid, phospholipids, vegetable oil or magnesium stearate.

6. The nutritional composition according to claim 1, characterized in that The nutritional composition is in the form of tablets, powders, granules, capsules or beverages.

7. Use of the nutritional composition according to any one of claims 1 to 6 in infant formula milk powder, infant complementary food or nutritional supplement.

8. The use according to claim 7, characterized in that The content of the nutritional composition in infant formula milk powder, infant complementary food or nutritional supplement is 5-20%, 5-10% or 20-50% by weight respectively.

Images